Literature DB >> 3726996

Isolation of dengue 2 and dengue 4 viruses from patients in Senegal.

J F Saluzzo, M Cornet, P Castagnet, C Rey, J P Digoutte.   

Abstract

Dengue 2 and dengue 4 viruses were isolated and re-isolated by inoculation into Aedes pseudoscutellaris continuous cell line (Mos 61) and/or Toxrhynchites brevipalpis. The strain of dengue 2 had been isolated from a patient returning from Casamance (south-western Senegal) and two strains of dengue 4 from patients who lived in Dakar and had not been outside the town in the 15 days before becoming ill. Serological evidence of dengue 4 infection was found in another patient living in Casamance.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3726996     DOI: 10.1016/0035-9203(86)90182-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  32 in total

1.  Sylvatic dengue viruses share the pathogenic potential of urban/endemic dengue viruses.

Authors:  Nikos Vasilakis; Jane Cardosa; Mawlouth Diallo; Amadou A Sall; Edward C Holmes; Kathryn A Hanley; Scott C Weaver; Javier Mota; Rebeca Rico-Hesse
Journal:  J Virol       Date:  2010-04       Impact factor: 5.103

Review 2.  Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health.

Authors:  Nikos Vasilakis; Jane Cardosa; Kathryn A Hanley; Edward C Holmes; Scott C Weaver
Journal:  Nat Rev Microbiol       Date:  2011-06-13       Impact factor: 60.633

3.  Infection dynamics of sylvatic dengue virus in a natural primate host, the African Green Monkey.

Authors:  Kathryn A Hanley; Mathilde Guerbois; Tiffany F Kautz; Meredith Brown; Stephen S Whitehead; Scott C Weaver; Nikos Vasilakis; Preston A Marx
Journal:  Am J Trop Med Hyg       Date:  2014-08-04       Impact factor: 2.345

Review 4.  Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.

Authors:  Kathryn A Hanley; Thomas P Monath; Scott C Weaver; Shannan L Rossi; Rebecca L Richman; Nikos Vasilakis
Journal:  Infect Genet Evol       Date:  2013-03-20       Impact factor: 3.342

5.  Acute arboviral infections in Guinea, West Africa, 2006.

Authors:  Emily S Jentes; Jaimie Robinson; Barbara W Johnson; Ibrahima Conde; Yosse Sakouvougui; Jennifer Iverson; Shanna Beecher; M Alpha Bah; Fousseny Diakite; Mamadi Coulibaly; Daniel G Bausch; Juliet Bryan
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

6.  Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Authors:  Anna P Durbin; Sandra V Mayer; Shannan L Rossi; Irma Y Amaya-Larios; Jose Ramos-Castaneda; Eng Eong Ooi; M Jane Cardosa; Jorge L Munoz-Jordan; Robert B Tesh; William B Messer; Scott C Weaver; Nikos Vasilakis
Journal:  Virology       Date:  2013-02-26       Impact factor: 3.616

7.  Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains.

Authors:  Nikos Vasilakis; Eric B Fokam; Christopher T Hanson; Ethan Weinberg; Amadou A Sall; Stephen S Whitehead; Kathryn A Hanley; Scott C Weaver
Journal:  Virology       Date:  2008-08-01       Impact factor: 3.616

8.  Evolutionary processes among sylvatic dengue type 2 viruses.

Authors:  Nikos Vasilakis; Edward C Holmes; Eric B Fokam; Ousmane Faye; Mawlouth Diallo; Amadou A Sall; Scott C Weaver
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

Review 9.  Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease.

Authors:  Scott C Weaver; Nikos Vasilakis
Journal:  Infect Genet Evol       Date:  2009-02-13       Impact factor: 3.342

10.  Amplification of the sylvatic cycle of dengue virus type 2, Senegal, 1999-2000: entomologic findings and epidemiologic considerations.

Authors:  Mawlouth Diallo; Yamar Ba; Amadou A Sall; Ousmane M Diop; Jacques A Ndione; Mireille Mondo; Lang Girault; Christian Mathiot
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.